Abstract

Dysregulated mitochondrial fusion and fission has been implicated in the pathogenesis of numerous diseases. We have identified a novel function of the p53 family protein TAp73 in regulating mitochondrial dynamics. TAp73 regulates the expression of Optic Atrophy 1 (OPA1), a protein responsible for controlling mitochondrial fusion, cristae biogenesis and electron transport chain function. Disruption of this axis results in a fragmented mitochondrial network and an impaired capacity for energy production via oxidative phosphorylation. Owing to the role of OPA1 in modulating cytochrome c release, TAp73−/− cells display an increased sensitivity to apoptotic cell death, e.g., via BH3-mimetics. We additionally show that the TAp73/OPA1 axis has functional relevance in the upper airway, where TAp73 expression is essential for multiciliated cell differentiation and function. Consistently, ciliated epithelial cells of Trp73−/− (global p73 knock-out) mice display decreased expression of OPA1 and perturbations of the mitochondrial network, which may drive multiciliated cell loss. In support of this, Trp73 and OPA1 gene expression is decreased in chronic obstructive pulmonary disease (COPD) patients, a disease characterised by alterations in mitochondrial dynamics. We therefore highlight a potential mechanism involving the loss of p73 in COPD pathogenesis. Our findings also add to the growing body of evidence for growth-promoting roles of TAp73 isoforms.

Details

Title
TAp73 regulates mitochondrial dynamics and multiciliated cell homeostasis through an OPA1 axis
Author
Buckley, Niall A. 1   VIAFID ORCID Logo  ; Craxton, Andrew 2 ; Sun, Xiao-Ming 2 ; Panatta, Emanuele 3   VIAFID ORCID Logo  ; Pinon, Lucia Giraldez 2 ; Beier, Sina 2 ; Kalmar, Lajos 2 ; Llodrá, Jaime 2 ; Morone, Nobuhiro 2 ; Amelio, Ivano 4   VIAFID ORCID Logo  ; Melino, Gerry 3   VIAFID ORCID Logo  ; Martins, L. Miguel 2 ; MacFarlane, Marion 2   VIAFID ORCID Logo 

 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); AstraZeneca, Safety Sciences, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Rome “Tor Vergata”, Department of Experimental Medicine, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941) 
 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Konstanz, Division for Systems Toxicology, Department of Biology, Konstanz, Germany (GRID:grid.9811.1) (ISNI:0000 0001 0658 7699) 
Pages
807
Publication year
2024
Publication date
Nov 2024
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3126244535
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.